




**a**



**b**





**Supplementary Figure 1. Crystallography of PI4KIIα with ADP bound. a,** A stereo image of overall 2Fo-Fc electron density map of PI4KIIα contoured at 1.0  $\sigma$ . **b,** 2Fo-Fc electron density map (1.0  $\sigma$ ) around the palmitoylation insertion, colored in green.




**Supplementary Figure 2. Analysis of the crystal packing of PI4KII $\alpha$ .** **a**, Superposition of the two PI4KII $\alpha$  molecules (A, yellow; B, pink) in one asymmetric unit. The significantly different conformations at the P-loop region and N-terminal helix  $\alpha$ 1 are indicated and labeled. **b**, Overall crystal packing of PI4KII $\alpha$  viewed along the **b** axis (left) and **c** axis (right). The unit cell is depicted and labeled. The two molecules of PI4KII $\alpha$  in one asymmetric unit are colored in yellow, molecule A, and pink, molecule B. Octamers (A<sub>8</sub> and B<sub>8</sub>) formed by each type of molecule are

indicated by respective rectangles. **c** and **d**, Overall structures of the octamers  $A_8$  and  $B_8$  are viewed from along (left) and perpendicular to (right) the membrane binding surface of PI4KII $\alpha$ . The bound ADP in each molecule is shown as a colored sphere. Color schemes for the rectangles are the same as in **b**.




### Supplementary Figure 3. Comparisons of the structures of PI4Ks and PI3Ks.



**a**, Known crystal structures of class I PI3K (p110  $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$ ), class III PI3K (vps34) and PIP4KII  $\beta$  are shown as cartoon diagrams with the structure of PI4KII $\alpha$  catalytic domain (colored in golden) superimposed, respectively. The views take the same angle as the crystal structure of PI4KII $\alpha$  in **Fig. 1c**. The N- and C-lobes of the catalytic domain are colored in blue and green, respectively. The catalytic loop and activation loop (if present) are colored in purple and red, respectively. The corresponding PDB code is shown below each structure. **b**, Structure-based sequence alignment of the catalytic domains of PI4KII $\alpha$  and PI3Ks. Structural superposition and the subsequent structure-based sequence alignment were performed using UCSF Chimera <sup>1</sup>. Secondary structures of PI4KII $\alpha$  are shown and labeled above the sequences, with blue for the N-lobe and green for the C-lobe; dashed lines represent untraced regions of the PI4KII $\alpha$  structure. Identical residues in the alignment are colored in black and similar residues in grey. Residues that contribute to nucleotide binding in PI4KII $\alpha$  are marked as solid circles with residues interacting with the phosphate moiety in red(●) and residues interacting with adenosine in cyan(●). GenBank accession numbers for the amino acid sequences of these proteins are Q9BTU6 for hPI4KII $\alpha$ , P42336 for hPI3K $\alpha$  (p110 $\alpha$ ), P42338 for hPI3K $\beta$  (p110 $\beta$ ), O00329 for hPI3K $\delta$  (p110 $\delta$ ), P48736 for hPI3K $\gamma$  (p110 $\gamma$ ) and Q9W1M7 for dVps34. The figure was prepared using Boxshade3.21 ([http://www.ch.embnet.org/software/BOX\\_form.html](http://www.ch.embnet.org/software/BOX_form.html)).



**Supplementary Figure 4. Sequence alignment of PI4KIIα around the G-loop region.** Ser134 and Ser137 residues are indicated with red triangles. The GenBank accession numbers of the PI4KIIα sequences from different species are NP\_060895 for *Homo sapiens*, NP\_998523 for *Daniorerio*, ACN11482 for *Salmosalar*, XP\_001929069 for *Susscrofa*, NP\_001093786 for *Bos Taurus*, XP\_002718643 for *Oryctolaguscuniculus*, NP\_663476 for *Musmusculus*, NP\_446187 for *Rattusnorvegicus*, NP\_001121279 for *Xenopuslaevis* and XP\_003366872 for *Trichinellaspiralis*. The GenBank accession numbers of the PI4KII β sequences from different species are NP\_060793 for *Homo sapiens*, NP\_001095534 for *Bos Taurus*, XP\_002709306 for *Oryctolaguscuniculus*, NP\_001005883 for *Rattusnorvegicus*, NP\_080227 for *Musmusculus*, XP\_002191179 for *Taeniopygiaguttata*, NP\_001026328 for *Gallus gallus*, NP\_001087050 for *Xenopuslaevis*, NP\_001038950 for *Daniorerio*, EFN64759 for *Camponotusfloridanus* and XP\_003378208 for *Trichinellaspiralis*. The alignment was performed using ClustalW and the figure was prepared with Boxshade3.21 ([http://www.ch.embnet.org/software/BOX\\_form.html](http://www.ch.embnet.org/software/BOX_form.html)).




**Supplementary Figure 5. Blue shifts in the internal fluorescence of Trp residues validates the membrane binding surface of PI4KII $\alpha$ .** In addition to the untraced Trp332 on insertion I2 and three non-exposed residues, Trp273, Trp314 and Trp366, the remaining four Trp residues (Trp359, Trp368, Trp166, Trp169) are exposed at the putative membrane-binding surface of PI4KII $\alpha$ . Internal tryptophan emission fluorescences of PI4KII $\alpha$  variants (PI4KII $\alpha$ <sup>SSPSS $\Delta$ C</sup> and PI4KII $\alpha$ <sup>FFPFF $\Delta$ C</sup>), which were in solution or reconstituted into liposomes, were measured at different protein concentrations, using the excitation wavelength at 295 nm.



**Supplementary Figure 6. Kinase activity of PI4KII $\alpha$  variants.** **a**, Kinase activity of PI4KII $\alpha$ <sup>SPSS $\Delta$ C</sup> increases when Triton X-100 is replaced by a zwitterionic detergent, dimethyl(3-sulfopropyl) tetradecyl-ammonium hydroxide (Anzergent3-14, AZ3-14, Anatrace<sup>®</sup>) since the “negatively-charged head” of AZ3-14 can enhance electrostatic interactions between PI4KII $\alpha$  and the surface of the detergent micelle. **b**, Comparison of the kinase activities of PI4KII $\alpha$  variants measured at conditions PI/0.2% TX-100 and PI/0.1% AZ3-14. Error bars represent the standard deviation (s.d.) from three independent experiments.






**Supplementary Figure 7. Structural characterization of PI4KII $\alpha$  in molecular dynamics simulations.** **a**, Time evolution of RMSD of PI4KII $\alpha$  relative to the crystal structure, with #1, #2 and #3 representing simulations of non-palmitoylated proteins, #4, #5 and #6 simulations of palmitoylated ones and #7 a simulation of membrane-free non-palmitoylated PI4KII $\alpha$ . In simulations #1 and #2, the crystal structure of PI4KII $\alpha$  was placed at  $t = 0$  ns on top of the PI-containing membrane at a distance of 20 Å while in simulation #3 the distance was 10 Å. The average RMSD of non-palmitoylated and palmitoylated proteins relative to the crystal structure over the last 700 ns of 1- $\mu$ s simulation were 3.59 Å and 2.64 Å, respectively. **b**, Time evolution of the relative height of the protein's center of mass with respect to upper lipid phosphate atoms' center of mass in different simulations. The choice of color is the same as in (a). **c**, Time evolution of the insertion depth of PI4KII $\alpha$ 's palmitoylation insertion (residue 166 to 179) center of

mass with respect to upper lipid phosphate atoms' center of mass. Negative values correspond to insertion of the loop into the membrane. The choice of color is the same as in (a). **d**, Conformational fluctuations of non-palmitoylated PI4KII $\alpha$  in the absence of interactions with a membrane. The black curve represents the membrane-free simulation of PI4KII $\alpha$ ; blue and dark-green curves were obtained from the first 100 ns of non-palmitoylated PI4KII $\alpha$  simulated in the presence of a membrane (#1 and #2 in a, b and c). The protein did not interact with the membrane during the first 100 ns of simulations #1 and #2., The RMSF was calculated using C $_{\alpha}$ -atoms of each protein residue (residue 107 to 453) through the indicated simulation time. For this purpose, the proteins were aligned to the crystal structure using backbone atoms without three insertions.

**a**

	Vmax ( $\mu\text{mol}/(\text{L}\cdot\text{min})$ )	Km (mmol/L)
PI4KII $\alpha^{\text{FFPFF}}$	388.4 $\pm$ 97.1	1.0 $\pm$ 0.3
PI4KII $\alpha^{\text{CCPCC}}$	53.1 $\pm$ 2.9	0.26 $\pm$ 0.04
P-Value	0.004	0.01


**b**

**Supplementary Figure 8. Enzymatic assays of PI4KII $\alpha$  variants.** **a.** Enzymatic  $V_{\text{max}}$  and  $K_{\text{m}}$  of PI4KII $\alpha$  variants. Lipid kinase activity of purified PI4KII $\alpha^{\text{FFPFF}}$  and PI4KII $\alpha^{\text{CCPCC}}$  (0.5  $\mu\text{g}$ ) was determined with the ADP-Glo<sup>TM</sup> kinase kit (Promega). Effects of palmitoylation motif mutation on the kinetics of PI4KII $\alpha$  catalysis were measured.  $V_{\text{max}}$  and  $K_{\text{m}}$  values for PI were calculated based on dose-dependent curves. Values are presented as means  $\pm$  S.D. from three independent experiments (student's *t*-test). **b.** Lipid kinase activity of PI4KII $\alpha$  variants on liposome with or without cholesterol. Proteoliposome of PI4KII $\alpha$  variants were made according to **METHODS** with the lipid composition, 20% DOPE, 10% DOPS,


10% DOPA, 10% PI and 50% DOPC for the cholesterol-free system and 20% DOPE, 10% DOPS, 10% DOPA, 10% PI, 40% DOPC and 10% cholesterol for the cholesterol-containing system. The kinase reaction was initiated by adding 0.1 mM ATP and the kinase activity was plotted by monitoring ADP generation with the ADP-Glo™ kinase kit (Promega). The error bars represent means  $\pm$  S.D. from three independent experiments. The binding efficiencies of PI4KII $\alpha$  variants to the liposome membrane were evaluated from the co-sedimentation experiments below. W: the whole amount of the proteoliposome; S, the supernatant after centrifuge of the proteoliposome; P, the precipitate after centrifuging the proteoliposome. Uncropped images of gels are shown in **Supplementary Fig. 9**.

## Supplementary Figure 9


### Figure 3a



### Figure 3b



**Supplementary Fig. 8b**



**Supplementary Figure 9. Full scans of original Western blots and gels for data in Figure 3 and Supplementary Fig. 8. Panels corresponding to the figures in the paper are indicated.**

**Supplementary Table 1. Mutant constructs used in this study**

Region	Name	Fragment	Mutation	Plasmids	Expression
Control	PI4KII $\alpha$ <sup>E<math>\Delta</math>N93</sup>	94-479	none	pFastBac	Insect cell (Hi5)
	PI4KII $\alpha$ <sup>CCPCC</sup>	78-479	none	pGEX-6P-1	<i>E. coli</i>
Palmitoylation motif and C terminal region (454-479)	PI4KII $\alpha$ <sup>SSPSS</sup>	78-479	<sup>174</sup> SSPSS <sup>178</sup>	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>SSPSS<math>\Delta</math>C</sup>	78-453	<sup>174</sup> SSPSS <sup>178</sup>	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>FFPFF</sup>	78-479	<sup>174</sup> FFPFF <sup>178</sup>	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>FFPFF<math>\Delta</math>C</sup>	78-453	<sup>174</sup> FFPFF <sup>178</sup>	pGEX-6P-1	<i>E. coli</i>
Nucleotide binding site	PI4KII $\alpha$ <sup>F263A/I345A</sup>	78-453	<sup>174</sup> FFPFF <sup>178</sup> / F263A/I345A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>D269A</sup>	78-453	<sup>174</sup> FFPFF <sup>178</sup> / D269A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>K152A</sup>	78-453	<sup>174</sup> FFPFF <sup>178</sup> / K152A	pGEX-6P-1	<i>E. coli</i>
PI binding site	PI4KII $\alpha$ <sup>E157A/Y159A</sup>	78-479	E157A/Y159A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>L184A/L349A</sup>	78-479	L184A/L349A	pGEX-6P-1	<i>E. coli</i>
Amphipathic $\alpha$ -helix of the palmitoylation insertion	PI4KII $\alpha$ <sup>W166A</sup>	78-479	W166A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>W169A</sup>	78-479	W169A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>L170A</sup>	78-479	L170A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>L173A</sup>	78-479	L173A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>W166A/W169A/ L170A/L173A</sup>	78-479	W166A/W169A/ L170A/L173A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>K165A/K168A/ K172A</sup>	78-479	K165A/K168A/ K172A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>K165E/K168E/ K172E</sup>	78-479	K165E/K168E/ K172E	pGEX-6P-1	<i>E. coli</i>
Membrane binding sites	PI4KII $\alpha$ <sup>W359A</sup>	78-479	W359A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>Y365A</sup>	78-479	Y365A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>W368A</sup>	78-479	W368A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>W359A/ Y365A/ W368A</sup>	78-479	W359A/ Y365A/ W368A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>R129A/R275A/ R276A</sup>	78-479	R129A/R275A/ R276A	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>R129E/R275E/ R276E</sup>	78-479	R129E/R275E/ R276E	pGEX-6P-1	<i>E. coli</i>
	PI4KII $\alpha$ <sup>R129A</sup>	78-479	R129A	pGEX-6P-1	<i>E. coli</i>

## Supplementary Note 1

CHARMM36 force field <sup>2-4</sup> and the TIP3P water model <sup>5</sup> were used in all simulations. The simulations were carried out in an NPT ensemble; temperature was maintained at 310 K through a Langevin thermostat with a damping coefficient of 0.5 ps<sup>-1</sup>; pressure was maintained at 1 atm with a Langevin-piston barostat <sup>6</sup>. Short-range non-bonded interactions were cut off smoothly between 1 and 1.2 nm; long-range electrostatics was computed with the PME algorithm <sup>7</sup>; simulations were performed with an integration time step of 2 fs in NAMD 2.9 <sup>8</sup>.

For the force field of the palmitoylated cysteine residue, initial parameters were obtained from the amino acid cysteine and from the dioleoylphosphatidylcholine (DOPC) lipid tail, employing the corresponding CHARMM36 force field <sup>4</sup>. The full cysteine residue and the first three carbons of the palmitoylation group were selected for further optimization by the force field toolkit (FFTK) <sup>9</sup> plugin of VMD <sup>10</sup>. Partial atomic charges were optimized from water-interaction profiles by Gaussian <sup>11</sup> at a HF/6-31G(d) level of theory. Hydrogen atom charges were kept at 0.09e to be consistent with the CHARMM force field <sup>12</sup>. Bond and angle parameters were optimized from distortions along internal coordinates by means of a QM Hessian matrix calculation at a MP2/6-31G(d) level of theory. Dihedral terms using torsion scans were optimized at a MP2/6-31G(d) level of theory. Final parameters for palmitoylated cysteine residue are shown below.

Topology file:

ATOM	N	NH1	-0.47
ATOM	HN	H	0.31
ATOM	CA	CT1	0.07
ATOM	HA	HB1	0.09
GROUP		!	HA-CA--CB--SG
ATOM	1CB	CT2	-0.10
ATOM	HB1	HA2	0.09
ATOM	HB2	HA2	0.09



ATOM	1SG	SM	-0.08
GROUP			
ATOM	C	C	0.51
ATOM	O	O	-0.51
GROUP		!	beta4
ATOM	C31	CL	0.67
ATOM	O32	OBL	-0.63
ATOM	C32	CTL2	-0.22
ATOM	H2X	HAL2	0.09
ATOM	H2Y	HAL2	0.09
GROUP			
ATOM	C33	CTL2	-0.18
ATOM	H3X	HAL2	0.09
ATOM	H3Y	HAL2	0.09
GROUP			
ATOM	C34	CTL2	-0.18
ATOM	H4X	HAL2	0.09
ATOM	H4Y	HAL2	0.09
GROUP			
ATOM	C35	CTL2	-0.18
ATOM	H5X	HAL2	0.09
ATOM	H5Y	HAL2	0.09
GROUP			
ATOM	C36	CTL2	-0.18
ATOM	H6X	HAL2	0.09
ATOM	H6Y	HAL2	0.09
GROUP			
ATOM	C37	CTL2	-0.18
ATOM	H7X	HAL2	0.09
ATOM	H7Y	HAL2	0.09
GROUP			
ATOM	C38	CTL2	-0.18
ATOM	H8X	HAL2	0.09
ATOM	H8Y	HAL2	0.09
GROUP			
ATOM	C39	CTL2	-0.18
ATOM	H9X	HAL2	0.09
ATOM	H9Y	HAL2	0.09
GROUP			
ATOM	C310	CTL2	-0.18
ATOM	H10X	HAL2	0.09
ATOM	H10Y	HAL2	0.09

GROUP			
ATOM	C311	CTL2	-0.18
ATOM	H11X	HAL2	0.09
ATOM	H11Y	HAL2	0.09
GROUP			
ATOM	C312	CTL2	-0.18
ATOM	H12X	HAL2	0.09
ATOM	H12Y	HAL2	0.09
GROUP			
ATOM	C313	CTL2	-0.18
ATOM	H13X	HAL2	0.09
ATOM	H13Y	HAL2	0.09
GROUP			
ATOM	C314	CTL2	-0.18
ATOM	H14X	HAL2	0.09
ATOM	H14Y	HAL2	0.09
GROUP			
ATOM	C315	CTL2	-0.18
ATOM	H15X	HAL2	0.09
ATOM	H15Y	HAL2	0.09
GROUP			
ATOM	C316	CTL3	-0.27
ATOM	H16X	HAL3	0.09
ATOM	H16Y	HAL3	0.09
ATOM	H16Z	HAL3	0.09

Parameter file:

BONDS

SM	CL	188.316	1.800
----	----	---------	-------

ANGLES

CT2	SM	CL	93.502	105.512		
SM	CL	OBL	44.869	117.121		
SM	CL	CTL2	48.393	120.173		
CT1	CT2	SM	CL	1.0040	3	180.00
CT2	SM	CL	OBL	2.7020	1	0.00
CT2	SM	CL	OBL	2.6500	2	180.00
CT2	SM	CL	CTL2	2.4760	1	180.00

CT2	SM	CL	CTL2	2.2270	2	180.00
SM	CL	CTL2	HAL2	0.2320	3	0.00
HA2	CT2	SM	CL	0.7170	3	0.00

## Supplementary References

1. Pettersen, E.F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-12 (2004).
2. Schlenkrich, M., Brickmann, J., MacKerell Jr, A.D. & Karplus, M. An empirical potential energy function for phospholipids: criteria for parameter optimization and applications. in *Biological Membranes* 31-81 (Springer, 1996).
3. MacKerell, A.D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. *The Journal of Physical Chemistry B* **102**, 3586-3616 (1998).
4. Klauda, J.B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. *The Journal of Physical Chemistry B* **114**, 7830-7843 (2010).
5. Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W. & Klein, M.L. Comparison of simple potential functions for simulating liquid water. *The Journal of Chemical Physics* **79**, 926-935 (1983).
6. Martyna, G.J., Tobias, D.J. & Klein, M.L. Constant pressure molecular dynamics algorithms. *The Journal of Chemical Physics* **101**, 4177 (1994).
7. Darden, T., Toukmaji, A. & Pedersen, L. Long-range electrostatic effects in biomolecular simulations. *Journal de chimie physique* **94**, 1346-1364 (1997).
8. Phillips, J.C. et al. Scalable molecular dynamics with NAMD. *Journal of Computational Chemistry* **26**, 1781-1802 (2005).
9. Mayne, C.G., Saam, J., Schulten, K., Tajkhorshid, E. & Gumbart, J.C. Rapid parameterization of small molecules using the Force Field Toolkit. *J Comput Chem* **34**, 2757-70 (2013).
10. Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. *Journal of Molecular Graphics* **14**, 33-38 (1996).
11. Frisch, M. et al. Gaussian 09, revision A. 02; Gaussian. Inc., Wallingford, CT **270**, 271 (2009).
12. Yin, D. & MacKerell, A.D. Combined ab initio/empirical approach for optimization of Lennard-Jones parameters. *Journal of Computational Chemistry* **19**, 334-348 (1998).